New frontiers in prostate cancer imaging: clinical utility of prostate-specific membrane antigen positron emission tomography

Published on Feb 14, 2017in International Urology and Nephrology1.843
· DOI :10.1007/S11255-017-1541-Y
Asim Afaq14
Estimated H-index: 14
(UCLH: University College London Hospitals NHS Foundation Trust),
Deepak Batura9
Estimated H-index: 9
(London North West Healthcare NHS Trust),
Jamshed Bomanji12
Estimated H-index: 12
(UCLH: University College London Hospitals NHS Foundation Trust)
Prostate-specific membrane antigen positron emission tomography (PSMA PET) is a relatively new method of imaging prostate cancer that increases diagnostic accuracy in detecting and guiding management in various stages of the disease pathway. Gallium-68-labelled PSMA PET has increased the sensitivity of detection of disease recurrence at low PSA levels, thus allowing an optimal window for salvage treatment. Apart from its use in disease recurrence, PSMA PET has the potential for increasing sensitivity and specificity for primary tumour localisation and in detecting lymph node disease, leading to a more accurate initial staging of the condition. In advanced disease, the use of PSMA PET may be able to assess response to treatment and also guide treatment with radionuclide therapy. Newer ligands under development might provide avenues for theranostic or personalised therapy applications with early data showing high PSA response rates. The rate of translation of PSMA PET into clinical practice has been remarkable. The use of this modality is likely to increase with future efforts to modify the radiotracer including 18F labelling to improve availability.
📖 Papers frequently viewed together
286 Citations
93 Citations
1 Citations
#1Thorsten Derlin (MHH: Hannover Medical School)H-Index: 30
#2Matthias Eiber (TUM: Technische Universität München)H-Index: 55
Last. Frank M. Bengel (MHH: Hannover Medical School)H-Index: 70
view all 4 authors...
10 CitationsSource
#1Clemens Kratochwil (University Hospital Heidelberg)H-Index: 54
#2Frederik L. Giesel (DKFZ: German Cancer Research Center)H-Index: 60
Last. Uwe Haberkorn (DKFZ: German Cancer Research Center)H-Index: 85
view all 10 authors...
UNLABELLED: Prostate-specific membrane antigen (PSMA) is an excellent target for radionuclide therapy of metastasized castration-resistant prostate cancer (mCRPC). Besides high affinity and long tumor retention, the DOTA-conjugated ligand PSMA-617 has low kidney uptake, making it an excellent choice for therapeutic application. We retrospectively report our experience with (177)Lu-PSMA-617-targeted radionuclide therapy in a case series of mCRPC patients resistant to other treatments. METHODS: Pa...
292 CitationsSource
#1Isabel Rauscher (TUM: Technische Universität München)H-Index: 20
#2Tobias Maurer (TUM: Technische Universität München)H-Index: 53
Last. Matthias Eiber (TUM: Technische Universität München)H-Index: 55
view all 6 authors...
Recently, positron emission tomography (PET) imaging using PSMA-ligands has gained high attention as a promising new radiotracer in patients with prostate cancer (PC). Several studies promise accurate staging of primary prostate cancer and restaging after biochemical recurrence with 68Ga-PSMA ligand Positron emission tomography/computed tomography (PET/CT). However, prospective trials and clinical guidelines for this new technique are still missing. Therefore, we summarized our experience with 6...
128 CitationsSource
#1Tobias Maurer (TUM: Technische Universität München)H-Index: 53
#2Jürgen E. Gschwend (TUM: Technische Universität München)H-Index: 57
Last. Matthias Eiber (TUM: Technische Universität München)H-Index: 55
view all 12 authors...
Purpose: Current standard imaging techniques are insufficient to reliably detect lymph node metastases in prostate cancer. Recently ligands of PSMA (prostate specific membrane antigen) were introduced in PET (positron emission tomography) of prostate cancer. Thus the aims of this retrospective analysis were to 1) investigate the diagnostic efficacy of 68Ga-PSMA-PET imaging for lymph node staging in patients with prostate cancer scheduled for radical prostatectomy and 2) compare it to morphologic...
447 CitationsSource
#1Tobias Maurer (TUM: Technische Universität München)H-Index: 53
#2Matthias Eiber (TUM: Technische Universität München)H-Index: 55
Last. Jürgen E. Gschwend (TUM: Technische Universität München)H-Index: 57
view all 4 authors...
Prostate-specific membrane antigen (PSMA) has gained increasing interest as target molecule for imaging. Several small compounds for labelling PSMA have been developed and are currently being investigated as imaging probes for PET. PSMA-based imaging has been reported to improve detection of metastatic disease compared with CT or multiparametric MRI and 68Ga-PSMA–PET imaging has been shown to increase detection of metastatic sites, therefore, it holds great promise to improve prostate cancer man...
286 CitationsSource
#1Lars BudäusH-Index: 33
Last. Clemens M. RosenbaumH-Index: 11
view all 9 authors...
Abstract Prostate-specific membrane antigen (PSMA) overexpression theoretically enables targeting of prostate cancer (PCa) metastases using gallium Ga 68 ( 68 Ga)–labeled PSMA ligands for positron emission tomography/computed tomography (PET/CT) imaging. Promising detection rates have been reported when using this approach for functional imaging of recurrent PCa; however, until now, the diagnostic accuracy of 68 Ga-PSMA PET/CT for preoperatively identifying lymph node metastases (LNMs) had not b...
285 CitationsSource
#1Hojjat Ahmadzadehfar (University Hospital Bonn)H-Index: 36
#2Elisabeth Eppard (University Hospital Bonn)H-Index: 11
Last. Markus Essler (University Hospital Bonn)H-Index: 37
view all 9 authors...
// Hojjat Ahmadzadehfar 1 , Elisabeth Eppard 1 , Stefan Kurpig 1 , Rolf Fimmers 2 , Anna Yordanova 1 , Carl Diedrich Schlenkhoff 1 , Florian Gartner 1 , Sebastian Rogenhofer 3 , Markus Essler 1 1 Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany 2 Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn, Bonn, Germany 3 Department of Urology, University Hospital Bonn, Bonn, Germany Correspondence to: Hojjat Ahmadzadehfar, e-mail: Hojjat.ahmadzadehfar...
159 CitationsSource
#1Martin T. Freitag (DKFZ: German Cancer Research Center)H-Index: 17
#2Jan Philipp Radtke (DKFZ: German Cancer Research Center)H-Index: 19
Last. Ali Afshar-Oromieh (University Hospital Heidelberg)H-Index: 37
view all 10 authors...
Purpose To evaluate the reproducibility of the combination of hybrid PET/MRI and the 68Ga-PSMA-11 tracer in depicting lymph node (LN) and bone metastases of prostate cancer (PC) in comparison with that of PET/CT.
113 CitationsSource
#2Phillip D. Stricker (Garvan Institute of Medical Research)H-Index: 56
Last. Louise Emmett (UNSW: University of New South Wales)H-Index: 30
view all 14 authors...
1Department of Diagnostic Imaging, St. Vincent’s Public Hospital, Sydney, Australia; 2Nuclear Medicine Operative Unit, Policlinico S. Orsola-Malpighi Hospital, Bologna, Italy; 3St. Vincent’s Prostate Cancer Centre, St. Vincent’s Clinic, Sydney, Australia; 4Australian Prostate Cancer Research Centre, Garvan Institute of Medical Research/Kinghorn Cancer Centre, Sydney, New South Wales, Australia; 5University of New South Wales, Sydney, New South Wales, Australia; and 6University of Sydney, Sydney,...
384 CitationsSource
#1Steven P. Rowe (Johns Hopkins University)H-Index: 32
#2Kenneth L. Gage (Johns Hopkins University)H-Index: 10
Last. Steve Y. Cho (Johns Hopkins University)H-Index: 18
view all 21 authors...
We previously demonstrated the ability to detect metastatic prostate cancer using N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-18F-fluorobenzyl-l-cysteine (18F-DCFBC), a low-molecular-weight radiotracer that targets the prostate-specific membrane antigen (PSMA). PSMA has been shown to be associated with higher Gleason grade and more aggressive disease. An imaging biomarker able to detect clinically significant high-grade primary prostate cancer reliably would address an unmet clinical need by allo...
144 CitationsSource
Cited By3
The [68Ga]PSMA PET/CT has been an option on clinical research tools to stage and to restage prostate cancer patients, although, with promising results, this radiopharmaceutical cannot be commercialized yet. Hence, up to date, [68Ga]PSMA has been used in a clinical research context. Once regulatory body approved it for marketing, health systems are responsible for the reimbursement decision. Health Technology Assessments (HTA) tools should be considered to base and to help decision-makers to spre...
2 CitationsSource
#1Sagnik Sengupta (IITI: Indian Institute of Technology Indore)H-Index: 3
#2Mena Asha Krishnan (IITI: Indian Institute of Technology Indore)H-Index: 3
Last. Venkatesh Chelvam (IITI: Indian Institute of Technology Indore)H-Index: 8
view all 4 authors...
Background Prostate-specific membrane antigen (PSMA), overexpressed on prostate cancer (PCa), is a well-characterized cell surface protein to selectively diagnose PCa. PSMA's unique characteristics and its 1000-fold higher expression in PCa compared with other tissues renders it as a suitable biomarker for detection of PCa in its early stage. In this report, we critically analyze and recommend the requirements needed for the development of variety of PSMA-targeted molecular imaging agents based ...
5 CitationsSource
#1Monzer Haj-Hamed (University of Cincinnati Academic Health Center)H-Index: 2
#2Vidhya Karivedu (UC: University of Cincinnati)H-Index: 5
Last. Abhinav Sidana (University of Cincinnati Academic Health Center)H-Index: 15
view all 3 authors...
Biochemical recurrence of prostate cancer occurs in 25–33% of patients who undergo radiation therapy (RT). Unfortunately, greater than 90% of patients with radiation recurrence undergo androgen deprivation therapy (ADT), despite the detrimental side effect profile and the lack of supporting evidence for ADT use in local recurrence. In patients who experience recurrence after treatment with RT, options for treatment include salvage radical prostatectomy (SRP), salvage cryotherapy (SCT), salvage b...
3 CitationsSource